#Sustainability #India #EcoVadis #Raichur #Shilpa Pharma

Shilpa Pharma Lifesciences Achieves EcoVadis Gold Medal

Shilpa Pharma Lifesciences Limited, a key subsidiary of Shilpa Medicare Limited, recently achieved a significant milestone by securing a Gold Medal from EcoVadis, renowned as a leading provider of sustainability ratings globally. This recognition highlights Shilpa's outstanding commitment to sustainability, showcased by an impressive score of 82 out of 100. This score places the company in the top 2% of over 130,000 businesses evaluated by EcoVadis, reflecting its strong Environmental, Social, and Governance (ESG) practices.

A Commitment to Excellence

Shilpa Pharma's performance in sustainability is judged based on four critical areas: Environment, Labor and Human Rights, Ethics, and Sustainable Procurement. This recognition places Shilpa Pharma among the elite group of companies recognized for their sustainable business operations, clearly illustrating its determination to operate as a responsible and resilient pharmaceutical entity.

Speaking on this commendable achievement, Mr. Keshav Bhutada, Executive Director and CEO of Shilpa Pharma Lifesciences, remarked, "Sustainability and innovation are at the core of Shilpa's growth strategy. The EcoVadis Gold Medal is a testament to our unwavering dedication to responsible manufacturing, ethical governance, and inclusive growth, which cultivates lasting value for our patients and partners. We are eager to collaborate with more global innovators in the future."

Strengthening Global Partnerships

This esteemed award not only signifies Shilpa Pharma’s dedication to sustainable practices but also bolsters its reputation among global customers, investors, and partners. It reinforces Shilpa’s positioning as a trusted partner in the Contract Development and Manufacturing Organization (CDMO) sector, with sustainability intricately woven into its operational framework.

Shilpa Pharma Lifesciences Limited specializes in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), formulations, and biologics, particularly in the fields of oncology, infectious diseases, and specialty segments. With expertise in complex generics, novel drug delivery systems, and CDMO services, Shilpa continues to impact patients' lives in over 80 countries worldwide.

Looking to the Future

As Shilpa Pharma Lifesciences moves forward, the company remains focused on expansion and innovation within the pharmaceutical industry. The recognition from EcoVadis is aimed at enhancing its collaborative efforts with global innovator companies in their New Chemical Entity programs. Shilpa believes that by prioritizing sustainability in all its operations, it can continue to create solutions that cater to the evolving landscape of the pharmaceutical sector.

The roadmap ahead will involve further investment in eco-friendly practices to ensure that sustainability is not just a milestone, but a continuous journey toward better health outcomes and ethical business practices. The commitment to fostering a sustainable future stands firm, as Shilpa Pharma braves through the challenges posed by market dynamics and regulatory landscapes, further establishing itself as a leader in the pharmaceutical domain.

About Shilpa Medicare Limited

Shilpa Medicare Limited, listed on the BSE and NSE, is a prominent Indian pharmaceutical company dedicated to providing high-quality healthcare solutions across various therapeutic areas. The company’s focus on research, innovation, and sustainability remains at the forefront of their operational ethos, ensuring they remain a pivotal player in the global pharmaceutical market. For additional insights, visit www.vbshilpa.com.